Trial Profile
A phase I trial of ACH 2684 in healthy volunteers and patients with hepatitis C virus genotypes 1 or 3.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Feb 2013
Price :
$35
*
At a glance
- Drugs Deldeprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- 20 Feb 2013 Status changed from recruiting to completed as reported in an Achillion media release.
- 12 Nov 2012 Beneficial results in genotype-1 hepatitis C treatment-naive patients with cirrhosis were reported in an Achillion Pharmaceuticals media release.
- 09 Jan 2012 Results were presented in an Achillion Pharmaceuticals media release.